Envoy Medical Inc（COCH）财务数据COCHEnvoy Medical Inc

Evaluating the bottom line, Envoy Medical Inc maintains a gross margin of -269.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8389.39%, while the net margin is -5957.58%. These profitability ratios, combined with a Return on Equity (ROE) of 559.98%, provide a clear picture of how effectively COCH converts its operational activities into shareholder value.

In the context of the broader market, COCH competes directly with industry leaders such as YHNA and SVRN. With a market capitalization of $55.88M, it holds a leading position in the sector. When comparing efficiency, COCH's gross margin of -269.70% stands against YHNA's N/A and SVRN's 100.00%. Such benchmarking helps identify whether Envoy Medical Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows significant revenue growth in the past quarters, with Q2 2026 revenue at $51,000, up from $39,000 in Q1 2026. However, the company has consistently reported net losses, with Q2 2026 net income at -$5,982,000.